Opus Genetics is trading at $3.99 (+10.53%) in pre-market on August 17, 2026, after renewed attention to its completed enrollment in the registrational Phase 3 OPGx-LCA5 trial.

  • Dosing is expected to begin in the fourth quarter of 2026, with topline data expected by the end of 2027.
  • No new August 17 company announcement was identified; broader market support was comparatively modest.